GL1X · GenesisL1 explorer

MolNFT v1 · #74448 · protein

X-ray structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range IC50 values

3OX3 · Ribosyldihydronicotinamide dehydrogenase [quinone]: “X-ray structural study of quinone reductase II inhibition by compounds with micromolar to nanomolar range…”. X-ray diffraction, 3 ligands (FAD, 4X4, ZN), 2 pockets (best…

PDB
3OX3
Type
protein
Length
455 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ribosyldihydronicotinamide dehydrogenase [quinone]
EC
1.10.99.2
UniProt
P16083
Ligands
FAD, 4X4, ZN
Pockets
2 · best druggability 0.77

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein22741% helix, 16% strandP16083
BRibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein22841% helix, 16% strandP16083

Ligands and binding sites

  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • 4X4 · N-[2-(2-methoxy-1H-dipyrido[2,3-a:3',2'-e]pyrrolizin-11-yl)ethyl]furan-2-carboxamide · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16340.770.8349FAD, 4X4
26070.760.82474X4, FAD

Interfaces

1 interface between chains.

  • A–B · 2033 Ų buried · 28 hydrogen bonds · protein-protein

Compared structures

  • 3OX3 · X-ray Structural study of qui reductase II inhibition by compounds with micromolar to… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.